Feature | Lung Imaging | October 26, 2015

Researchers confirm predictive capabilities of minimally invasive procedure that offers high accuracy for positive and negative diagnosis

University of Missouri, EBUS-TBFNA, lung cancer diagnosis

October 26, 2015 — University of Missouri researchers have developed a new scoring system for a common lung cancer diagnostic test that may help physicians better understand the risk for malignancy when evaluating patients.

Endobronchial ultrasound-guided transbronchial fine-needle aspiration, or EBUS-TBFNA, is a minimally invasive procedure often used for the initial diagnosis of many lung cancers. The test uses a thin, flexible scope that passes through the mouth and into the lungs to remove a small piece of tissue for evaluation. The test is commonly used because it can provide a rapid cancer diagnosis without the need for an invasive open procedure.

“The EBUS-TBFNA procedure is a diagnostic tool for lung cancer that yields proven results,” said Lester Layfield, M.D., professor and chair of the Department of Pathology and Anatomical Sciences at the MU School of Medicine and lead author of the study. “The test categorizes the results as ‘benign,’ ‘non-diagnostic,’ ‘atypical,’ ‘suspicious for malignancy’ or ‘malignant.’ Our goal with this study was to understand the risk of cancer associated with each category.”

Layfield’s research team evaluated information from 136 patients who received a diagnosis following the EBUS-TBFNA procedure. The same patients then had an open surgical procedure to confirm whether the tissue was cancerous or benign.

Layfield’s research team found that the EBUS-TBFNA tool provided an accurate positive diagnosis of lung cancer 84 percent of the time and an accurate negative diagnosis of lung cancer 68 percent of the time. The study also provided the research team with an estimation of malignancy risks for each category, which in the future could help doctors offer patients enhanced care and counseling, Layfield said.

The study, “Malignancy Risk Associated with the EBUS-FNA Diagnostic Categories Nondiagnostic, Benign, Atypical, Suspicious for Malignancy, and Malignant for Mediastinal Lymph Node Aspirate Specimens,” recently was published in the Journal of the American Society of Cytopathology.

For more information: www.jascyto.org

Related Content

News | Lung Imaging

August 3, 2022 — Structural differences in lung airways between men and women may be the cause of differences in chronic ...

Time August 03, 2022
arrow
Feature | Lung Imaging

August 1, 2022 — In recognition of World Lung Cancer Day, the American Lung Association announced new patient resources ...

Time August 01, 2022
arrow
News | ECR

July 12, 2022 — Median Technologies (ALMDT) announced that the company will be participating in the 2022 European ...

Time July 12, 2022
arrow
News | Coronavirus (COVID-19)

June 27, 2022 — Three articles and an accompanying editorial provide information on the effects of Long COVID in the ...

Time June 28, 2022
arrow
News | Radiology Imaging

June 21, 2022 — After less than two years of data collection and processing, the Radiological Society of North America ...

Time June 21, 2022
arrow
News | Artificial Intelligence

June 14, 2022 — According to ARRS’ American Journal of Roentgenology (AJR), incorporating AI support into clinical ...

Time June 14, 2022
arrow
News | Breast Imaging

June 9, 2022 — DetectedX announced that it has been selected by the National Breast Screening Programme in Ireland ...

Time June 09, 2022
arrow
News | Digital Radiography (DR)

June 8, 2022 — MinXray continues to enhance the diagnostic capabilities of its digital radiography systems with the ...

Time June 08, 2022
arrow
News | Coronavirus (COVID-19)

June 1, 2022 — According to ARRS’ American Journal of Roentgenology (AJR), evaluating chest CT findings offers an ...

Time June 01, 2022
arrow
News | Ultrasound Imaging

May 25, 2022 — Researchers in Spain conducted a study to compare the diagnostic accuracy of lung ultrasounds (LUS) ...

Time May 25, 2022
arrow
Subscribe Now